Cost Effectiveness of Antiviral Treatment with Zalcitabine plus Zidovudine for AIDS Patients with CD4+ Counts Less Than 300/µ1 in 5 European Countries
Abstract Summary A cost-effectiveness model was developed on the basis of early clinical trial results from the US reporting sustained CD4+ cell response in patients receiving zalcitabine in addition to zidovudine. This model was then adapted and applied to 5 European countries to assess the compara...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Simpson, Kit [verfasserIn] Hatzialldreu, Evi J. [verfasserIn] Anderssoll, Fredrik [verfasserIn] Shakespeare, Annabelle [verfasserIn] Oleksy, Jnga [verfasserIn] Tosteson, Anna N.A. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1994 |
|---|
| Schlagwörter: |
Acquire Immune Deficiency Syndrome |
|---|
| Übergeordnetes Werk: |
Enthalten in: PharmacoEconomics - Berlin [u.a.] : Springer, 1992, 6(1994), 6 vom: Dez., Seite 553-562 |
|---|---|
| Übergeordnetes Werk: |
volume:6 ; year:1994 ; number:6 ; month:12 ; pages:553-562 |
| Links: |
|---|
| DOI / URN: |
10.2165/00019053-199406060-00008 |
|---|
| Katalog-ID: |
SPR033321167 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR033321167 | ||
| 003 | DE-627 | ||
| 005 | 20230519200604.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s1994 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2165/00019053-199406060-00008 |2 doi | |
| 035 | |a (DE-627)SPR033321167 | ||
| 035 | |a (SPR)00019053-199406060-00008-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Simpson, Kit |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cost Effectiveness of Antiviral Treatment with Zalcitabine plus Zidovudine for AIDS Patients with CD4+ Counts Less Than 300/µ1 in 5 European Countries |
| 264 | 1 | |c 1994 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Summary A cost-effectiveness model was developed on the basis of early clinical trial results from the US reporting sustained CD4+ cell response in patients receiving zalcitabine in addition to zidovudine. This model was then adapted and applied to 5 European countries to assess the comparative cost effectiveness of adding zaldtabine to antiviral treatment for AIDS patients. The countries included in the modelling effort were Switzerland, France, Italy, Germany and the UK. The model used a Markov state-transition process to estimate the rate of acute opportunistic disease episodes, li fetime medical treatment costs, and survival for pop. ulations of AIDS patients with baseline CD4+ counts of less than 300/]l1. Physic ian panels in each country developed standard treatment algorithms and adjusted the epidemiological data to renect the AIDS profile of each country. Economic consultants provided cost data. Results from this exploratory data analysis show that if CD4+ counts correlate with the incidence of opportunistic disease episodes as expected, the combined use of zalcitabine and zidovudinc for a 1-year period should be cost effective. | ||
| 650 | 4 | |a Zidovudine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Acquire Immune Deficiency Syndrome |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Zalcitabine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Acquire Immune Deficiency Syndrome Patient |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Medical Care System |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Hatzialldreu, Evi J. |e verfasserin |4 aut | |
| 700 | 1 | |a Anderssoll, Fredrik |e verfasserin |4 aut | |
| 700 | 1 | |a Shakespeare, Annabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Oleksy, Jnga |e verfasserin |4 aut | |
| 700 | 1 | |a Tosteson, Anna N.A. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PharmacoEconomics |d Berlin [u.a.] : Springer, 1992 |g 6(1994), 6 vom: Dez., Seite 553-562 |w (DE-627)327645717 |w (DE-600)2043876-X |x 1179-2027 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:1994 |g number:6 |g month:12 |g pages:553-562 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.2165/00019053-199406060-00008 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2190 | ||
| 936 | b | k | |a 44.40 |q ASE |
| 951 | |a AR | ||
| 952 | |d 6 |j 1994 |e 6 |c 12 |h 553-562 | ||
| author_variant |
k s ks e j h ej ejh f a fa a s as j o jo a n t an ant |
|---|---|
| matchkey_str |
article:11792027:1994----::otfetvnsoatvrlramnwtzliaielsiouieoadptetwtc4on |
| hierarchy_sort_str |
1994 |
| bklnumber |
44.40 |
| publishDate |
1994 |
| allfields |
10.2165/00019053-199406060-00008 doi (DE-627)SPR033321167 (SPR)00019053-199406060-00008-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Simpson, Kit verfasserin aut Cost Effectiveness of Antiviral Treatment with Zalcitabine plus Zidovudine for AIDS Patients with CD4+ Counts Less Than 300/µ1 in 5 European Countries 1994 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Summary A cost-effectiveness model was developed on the basis of early clinical trial results from the US reporting sustained CD4+ cell response in patients receiving zalcitabine in addition to zidovudine. This model was then adapted and applied to 5 European countries to assess the comparative cost effectiveness of adding zaldtabine to antiviral treatment for AIDS patients. The countries included in the modelling effort were Switzerland, France, Italy, Germany and the UK. The model used a Markov state-transition process to estimate the rate of acute opportunistic disease episodes, li fetime medical treatment costs, and survival for pop. ulations of AIDS patients with baseline CD4+ counts of less than 300/]l1. Physic ian panels in each country developed standard treatment algorithms and adjusted the epidemiological data to renect the AIDS profile of each country. Economic consultants provided cost data. Results from this exploratory data analysis show that if CD4+ counts correlate with the incidence of opportunistic disease episodes as expected, the combined use of zalcitabine and zidovudinc for a 1-year period should be cost effective. Zidovudine (dpeaa)DE-He213 Acquire Immune Deficiency Syndrome (dpeaa)DE-He213 Zalcitabine (dpeaa)DE-He213 Acquire Immune Deficiency Syndrome Patient (dpeaa)DE-He213 Medical Care System (dpeaa)DE-He213 Hatzialldreu, Evi J. verfasserin aut Anderssoll, Fredrik verfasserin aut Shakespeare, Annabelle verfasserin aut Oleksy, Jnga verfasserin aut Tosteson, Anna N.A. verfasserin aut Enthalten in PharmacoEconomics Berlin [u.a.] : Springer, 1992 6(1994), 6 vom: Dez., Seite 553-562 (DE-627)327645717 (DE-600)2043876-X 1179-2027 nnns volume:6 year:1994 number:6 month:12 pages:553-562 https://dx.doi.org/10.2165/00019053-199406060-00008 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 6 1994 6 12 553-562 |
| spelling |
10.2165/00019053-199406060-00008 doi (DE-627)SPR033321167 (SPR)00019053-199406060-00008-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Simpson, Kit verfasserin aut Cost Effectiveness of Antiviral Treatment with Zalcitabine plus Zidovudine for AIDS Patients with CD4+ Counts Less Than 300/µ1 in 5 European Countries 1994 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Summary A cost-effectiveness model was developed on the basis of early clinical trial results from the US reporting sustained CD4+ cell response in patients receiving zalcitabine in addition to zidovudine. This model was then adapted and applied to 5 European countries to assess the comparative cost effectiveness of adding zaldtabine to antiviral treatment for AIDS patients. The countries included in the modelling effort were Switzerland, France, Italy, Germany and the UK. The model used a Markov state-transition process to estimate the rate of acute opportunistic disease episodes, li fetime medical treatment costs, and survival for pop. ulations of AIDS patients with baseline CD4+ counts of less than 300/]l1. Physic ian panels in each country developed standard treatment algorithms and adjusted the epidemiological data to renect the AIDS profile of each country. Economic consultants provided cost data. Results from this exploratory data analysis show that if CD4+ counts correlate with the incidence of opportunistic disease episodes as expected, the combined use of zalcitabine and zidovudinc for a 1-year period should be cost effective. Zidovudine (dpeaa)DE-He213 Acquire Immune Deficiency Syndrome (dpeaa)DE-He213 Zalcitabine (dpeaa)DE-He213 Acquire Immune Deficiency Syndrome Patient (dpeaa)DE-He213 Medical Care System (dpeaa)DE-He213 Hatzialldreu, Evi J. verfasserin aut Anderssoll, Fredrik verfasserin aut Shakespeare, Annabelle verfasserin aut Oleksy, Jnga verfasserin aut Tosteson, Anna N.A. verfasserin aut Enthalten in PharmacoEconomics Berlin [u.a.] : Springer, 1992 6(1994), 6 vom: Dez., Seite 553-562 (DE-627)327645717 (DE-600)2043876-X 1179-2027 nnns volume:6 year:1994 number:6 month:12 pages:553-562 https://dx.doi.org/10.2165/00019053-199406060-00008 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 6 1994 6 12 553-562 |
| allfields_unstemmed |
10.2165/00019053-199406060-00008 doi (DE-627)SPR033321167 (SPR)00019053-199406060-00008-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Simpson, Kit verfasserin aut Cost Effectiveness of Antiviral Treatment with Zalcitabine plus Zidovudine for AIDS Patients with CD4+ Counts Less Than 300/µ1 in 5 European Countries 1994 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Summary A cost-effectiveness model was developed on the basis of early clinical trial results from the US reporting sustained CD4+ cell response in patients receiving zalcitabine in addition to zidovudine. This model was then adapted and applied to 5 European countries to assess the comparative cost effectiveness of adding zaldtabine to antiviral treatment for AIDS patients. The countries included in the modelling effort were Switzerland, France, Italy, Germany and the UK. The model used a Markov state-transition process to estimate the rate of acute opportunistic disease episodes, li fetime medical treatment costs, and survival for pop. ulations of AIDS patients with baseline CD4+ counts of less than 300/]l1. Physic ian panels in each country developed standard treatment algorithms and adjusted the epidemiological data to renect the AIDS profile of each country. Economic consultants provided cost data. Results from this exploratory data analysis show that if CD4+ counts correlate with the incidence of opportunistic disease episodes as expected, the combined use of zalcitabine and zidovudinc for a 1-year period should be cost effective. Zidovudine (dpeaa)DE-He213 Acquire Immune Deficiency Syndrome (dpeaa)DE-He213 Zalcitabine (dpeaa)DE-He213 Acquire Immune Deficiency Syndrome Patient (dpeaa)DE-He213 Medical Care System (dpeaa)DE-He213 Hatzialldreu, Evi J. verfasserin aut Anderssoll, Fredrik verfasserin aut Shakespeare, Annabelle verfasserin aut Oleksy, Jnga verfasserin aut Tosteson, Anna N.A. verfasserin aut Enthalten in PharmacoEconomics Berlin [u.a.] : Springer, 1992 6(1994), 6 vom: Dez., Seite 553-562 (DE-627)327645717 (DE-600)2043876-X 1179-2027 nnns volume:6 year:1994 number:6 month:12 pages:553-562 https://dx.doi.org/10.2165/00019053-199406060-00008 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 6 1994 6 12 553-562 |
| allfieldsGer |
10.2165/00019053-199406060-00008 doi (DE-627)SPR033321167 (SPR)00019053-199406060-00008-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Simpson, Kit verfasserin aut Cost Effectiveness of Antiviral Treatment with Zalcitabine plus Zidovudine for AIDS Patients with CD4+ Counts Less Than 300/µ1 in 5 European Countries 1994 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Summary A cost-effectiveness model was developed on the basis of early clinical trial results from the US reporting sustained CD4+ cell response in patients receiving zalcitabine in addition to zidovudine. This model was then adapted and applied to 5 European countries to assess the comparative cost effectiveness of adding zaldtabine to antiviral treatment for AIDS patients. The countries included in the modelling effort were Switzerland, France, Italy, Germany and the UK. The model used a Markov state-transition process to estimate the rate of acute opportunistic disease episodes, li fetime medical treatment costs, and survival for pop. ulations of AIDS patients with baseline CD4+ counts of less than 300/]l1. Physic ian panels in each country developed standard treatment algorithms and adjusted the epidemiological data to renect the AIDS profile of each country. Economic consultants provided cost data. Results from this exploratory data analysis show that if CD4+ counts correlate with the incidence of opportunistic disease episodes as expected, the combined use of zalcitabine and zidovudinc for a 1-year period should be cost effective. Zidovudine (dpeaa)DE-He213 Acquire Immune Deficiency Syndrome (dpeaa)DE-He213 Zalcitabine (dpeaa)DE-He213 Acquire Immune Deficiency Syndrome Patient (dpeaa)DE-He213 Medical Care System (dpeaa)DE-He213 Hatzialldreu, Evi J. verfasserin aut Anderssoll, Fredrik verfasserin aut Shakespeare, Annabelle verfasserin aut Oleksy, Jnga verfasserin aut Tosteson, Anna N.A. verfasserin aut Enthalten in PharmacoEconomics Berlin [u.a.] : Springer, 1992 6(1994), 6 vom: Dez., Seite 553-562 (DE-627)327645717 (DE-600)2043876-X 1179-2027 nnns volume:6 year:1994 number:6 month:12 pages:553-562 https://dx.doi.org/10.2165/00019053-199406060-00008 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 6 1994 6 12 553-562 |
| allfieldsSound |
10.2165/00019053-199406060-00008 doi (DE-627)SPR033321167 (SPR)00019053-199406060-00008-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Simpson, Kit verfasserin aut Cost Effectiveness of Antiviral Treatment with Zalcitabine plus Zidovudine for AIDS Patients with CD4+ Counts Less Than 300/µ1 in 5 European Countries 1994 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Summary A cost-effectiveness model was developed on the basis of early clinical trial results from the US reporting sustained CD4+ cell response in patients receiving zalcitabine in addition to zidovudine. This model was then adapted and applied to 5 European countries to assess the comparative cost effectiveness of adding zaldtabine to antiviral treatment for AIDS patients. The countries included in the modelling effort were Switzerland, France, Italy, Germany and the UK. The model used a Markov state-transition process to estimate the rate of acute opportunistic disease episodes, li fetime medical treatment costs, and survival for pop. ulations of AIDS patients with baseline CD4+ counts of less than 300/]l1. Physic ian panels in each country developed standard treatment algorithms and adjusted the epidemiological data to renect the AIDS profile of each country. Economic consultants provided cost data. Results from this exploratory data analysis show that if CD4+ counts correlate with the incidence of opportunistic disease episodes as expected, the combined use of zalcitabine and zidovudinc for a 1-year period should be cost effective. Zidovudine (dpeaa)DE-He213 Acquire Immune Deficiency Syndrome (dpeaa)DE-He213 Zalcitabine (dpeaa)DE-He213 Acquire Immune Deficiency Syndrome Patient (dpeaa)DE-He213 Medical Care System (dpeaa)DE-He213 Hatzialldreu, Evi J. verfasserin aut Anderssoll, Fredrik verfasserin aut Shakespeare, Annabelle verfasserin aut Oleksy, Jnga verfasserin aut Tosteson, Anna N.A. verfasserin aut Enthalten in PharmacoEconomics Berlin [u.a.] : Springer, 1992 6(1994), 6 vom: Dez., Seite 553-562 (DE-627)327645717 (DE-600)2043876-X 1179-2027 nnns volume:6 year:1994 number:6 month:12 pages:553-562 https://dx.doi.org/10.2165/00019053-199406060-00008 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 6 1994 6 12 553-562 |
| language |
English |
| source |
Enthalten in PharmacoEconomics 6(1994), 6 vom: Dez., Seite 553-562 volume:6 year:1994 number:6 month:12 pages:553-562 |
| sourceStr |
Enthalten in PharmacoEconomics 6(1994), 6 vom: Dez., Seite 553-562 volume:6 year:1994 number:6 month:12 pages:553-562 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Zidovudine Acquire Immune Deficiency Syndrome Zalcitabine Acquire Immune Deficiency Syndrome Patient Medical Care System |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
PharmacoEconomics |
| authorswithroles_txt_mv |
Simpson, Kit @@aut@@ Hatzialldreu, Evi J. @@aut@@ Anderssoll, Fredrik @@aut@@ Shakespeare, Annabelle @@aut@@ Oleksy, Jnga @@aut@@ Tosteson, Anna N.A. @@aut@@ |
| publishDateDaySort_date |
1994-12-01T00:00:00Z |
| hierarchy_top_id |
327645717 |
| dewey-sort |
3610 |
| id |
SPR033321167 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR033321167</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519200604.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1994 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00019053-199406060-00008</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR033321167</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00019053-199406060-00008-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Simpson, Kit</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cost Effectiveness of Antiviral Treatment with Zalcitabine plus Zidovudine for AIDS Patients with CD4+ Counts Less Than 300/µ1 in 5 European Countries</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1994</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Summary A cost-effectiveness model was developed on the basis of early clinical trial results from the US reporting sustained CD4+ cell response in patients receiving zalcitabine in addition to zidovudine. This model was then adapted and applied to 5 European countries to assess the comparative cost effectiveness of adding zaldtabine to antiviral treatment for AIDS patients. The countries included in the modelling effort were Switzerland, France, Italy, Germany and the UK. The model used a Markov state-transition process to estimate the rate of acute opportunistic disease episodes, li fetime medical treatment costs, and survival for pop. ulations of AIDS patients with baseline CD4+ counts of less than 300/]l1. Physic ian panels in each country developed standard treatment algorithms and adjusted the epidemiological data to renect the AIDS profile of each country. Economic consultants provided cost data. Results from this exploratory data analysis show that if CD4+ counts correlate with the incidence of opportunistic disease episodes as expected, the combined use of zalcitabine and zidovudinc for a 1-year period should be cost effective.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Zidovudine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acquire Immune Deficiency Syndrome</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Zalcitabine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acquire Immune Deficiency Syndrome Patient</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medical Care System</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hatzialldreu, Evi J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Anderssoll, Fredrik</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shakespeare, Annabelle</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oleksy, Jnga</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tosteson, Anna N.A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">PharmacoEconomics</subfield><subfield code="d">Berlin [u.a.] : Springer, 1992</subfield><subfield code="g">6(1994), 6 vom: Dez., Seite 553-562</subfield><subfield code="w">(DE-627)327645717</subfield><subfield code="w">(DE-600)2043876-X</subfield><subfield code="x">1179-2027</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:6</subfield><subfield code="g">year:1994</subfield><subfield code="g">number:6</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:553-562</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00019053-199406060-00008</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">6</subfield><subfield code="j">1994</subfield><subfield code="e">6</subfield><subfield code="c">12</subfield><subfield code="h">553-562</subfield></datafield></record></collection>
|
| author |
Simpson, Kit |
| spellingShingle |
Simpson, Kit ddc 610 bkl 44.40 misc Zidovudine misc Acquire Immune Deficiency Syndrome misc Zalcitabine misc Acquire Immune Deficiency Syndrome Patient misc Medical Care System Cost Effectiveness of Antiviral Treatment with Zalcitabine plus Zidovudine for AIDS Patients with CD4+ Counts Less Than 300/µ1 in 5 European Countries |
| authorStr |
Simpson, Kit |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)327645717 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1179-2027 |
| topic_title |
610 ASE 44.40 bkl Cost Effectiveness of Antiviral Treatment with Zalcitabine plus Zidovudine for AIDS Patients with CD4+ Counts Less Than 300/µ1 in 5 European Countries Zidovudine (dpeaa)DE-He213 Acquire Immune Deficiency Syndrome (dpeaa)DE-He213 Zalcitabine (dpeaa)DE-He213 Acquire Immune Deficiency Syndrome Patient (dpeaa)DE-He213 Medical Care System (dpeaa)DE-He213 |
| topic |
ddc 610 bkl 44.40 misc Zidovudine misc Acquire Immune Deficiency Syndrome misc Zalcitabine misc Acquire Immune Deficiency Syndrome Patient misc Medical Care System |
| topic_unstemmed |
ddc 610 bkl 44.40 misc Zidovudine misc Acquire Immune Deficiency Syndrome misc Zalcitabine misc Acquire Immune Deficiency Syndrome Patient misc Medical Care System |
| topic_browse |
ddc 610 bkl 44.40 misc Zidovudine misc Acquire Immune Deficiency Syndrome misc Zalcitabine misc Acquire Immune Deficiency Syndrome Patient misc Medical Care System |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
PharmacoEconomics |
| hierarchy_parent_id |
327645717 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
PharmacoEconomics |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)327645717 (DE-600)2043876-X |
| title |
Cost Effectiveness of Antiviral Treatment with Zalcitabine plus Zidovudine for AIDS Patients with CD4+ Counts Less Than 300/µ1 in 5 European Countries |
| ctrlnum |
(DE-627)SPR033321167 (SPR)00019053-199406060-00008-e |
| title_full |
Cost Effectiveness of Antiviral Treatment with Zalcitabine plus Zidovudine for AIDS Patients with CD4+ Counts Less Than 300/µ1 in 5 European Countries |
| author_sort |
Simpson, Kit |
| journal |
PharmacoEconomics |
| journalStr |
PharmacoEconomics |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
1994 |
| contenttype_str_mv |
txt |
| container_start_page |
553 |
| author_browse |
Simpson, Kit Hatzialldreu, Evi J. Anderssoll, Fredrik Shakespeare, Annabelle Oleksy, Jnga Tosteson, Anna N.A. |
| container_volume |
6 |
| class |
610 ASE 44.40 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Simpson, Kit |
| doi_str_mv |
10.2165/00019053-199406060-00008 |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for aids patients with cd4+ counts less than 300/µ1 in 5 european countries |
| title_auth |
Cost Effectiveness of Antiviral Treatment with Zalcitabine plus Zidovudine for AIDS Patients with CD4+ Counts Less Than 300/µ1 in 5 European Countries |
| abstract |
Abstract Summary A cost-effectiveness model was developed on the basis of early clinical trial results from the US reporting sustained CD4+ cell response in patients receiving zalcitabine in addition to zidovudine. This model was then adapted and applied to 5 European countries to assess the comparative cost effectiveness of adding zaldtabine to antiviral treatment for AIDS patients. The countries included in the modelling effort were Switzerland, France, Italy, Germany and the UK. The model used a Markov state-transition process to estimate the rate of acute opportunistic disease episodes, li fetime medical treatment costs, and survival for pop. ulations of AIDS patients with baseline CD4+ counts of less than 300/]l1. Physic ian panels in each country developed standard treatment algorithms and adjusted the epidemiological data to renect the AIDS profile of each country. Economic consultants provided cost data. Results from this exploratory data analysis show that if CD4+ counts correlate with the incidence of opportunistic disease episodes as expected, the combined use of zalcitabine and zidovudinc for a 1-year period should be cost effective. |
| abstractGer |
Abstract Summary A cost-effectiveness model was developed on the basis of early clinical trial results from the US reporting sustained CD4+ cell response in patients receiving zalcitabine in addition to zidovudine. This model was then adapted and applied to 5 European countries to assess the comparative cost effectiveness of adding zaldtabine to antiviral treatment for AIDS patients. The countries included in the modelling effort were Switzerland, France, Italy, Germany and the UK. The model used a Markov state-transition process to estimate the rate of acute opportunistic disease episodes, li fetime medical treatment costs, and survival for pop. ulations of AIDS patients with baseline CD4+ counts of less than 300/]l1. Physic ian panels in each country developed standard treatment algorithms and adjusted the epidemiological data to renect the AIDS profile of each country. Economic consultants provided cost data. Results from this exploratory data analysis show that if CD4+ counts correlate with the incidence of opportunistic disease episodes as expected, the combined use of zalcitabine and zidovudinc for a 1-year period should be cost effective. |
| abstract_unstemmed |
Abstract Summary A cost-effectiveness model was developed on the basis of early clinical trial results from the US reporting sustained CD4+ cell response in patients receiving zalcitabine in addition to zidovudine. This model was then adapted and applied to 5 European countries to assess the comparative cost effectiveness of adding zaldtabine to antiviral treatment for AIDS patients. The countries included in the modelling effort were Switzerland, France, Italy, Germany and the UK. The model used a Markov state-transition process to estimate the rate of acute opportunistic disease episodes, li fetime medical treatment costs, and survival for pop. ulations of AIDS patients with baseline CD4+ counts of less than 300/]l1. Physic ian panels in each country developed standard treatment algorithms and adjusted the epidemiological data to renect the AIDS profile of each country. Economic consultants provided cost data. Results from this exploratory data analysis show that if CD4+ counts correlate with the incidence of opportunistic disease episodes as expected, the combined use of zalcitabine and zidovudinc for a 1-year period should be cost effective. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 |
| container_issue |
6 |
| title_short |
Cost Effectiveness of Antiviral Treatment with Zalcitabine plus Zidovudine for AIDS Patients with CD4+ Counts Less Than 300/µ1 in 5 European Countries |
| url |
https://dx.doi.org/10.2165/00019053-199406060-00008 |
| remote_bool |
true |
| author2 |
Hatzialldreu, Evi J. Anderssoll, Fredrik Shakespeare, Annabelle Oleksy, Jnga Tosteson, Anna N.A. |
| author2Str |
Hatzialldreu, Evi J. Anderssoll, Fredrik Shakespeare, Annabelle Oleksy, Jnga Tosteson, Anna N.A. |
| ppnlink |
327645717 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.2165/00019053-199406060-00008 |
| up_date |
2024-07-03T17:56:07.807Z |
| _version_ |
1803581514378641408 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR033321167</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519200604.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1994 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00019053-199406060-00008</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR033321167</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00019053-199406060-00008-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Simpson, Kit</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cost Effectiveness of Antiviral Treatment with Zalcitabine plus Zidovudine for AIDS Patients with CD4+ Counts Less Than 300/µ1 in 5 European Countries</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1994</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Summary A cost-effectiveness model was developed on the basis of early clinical trial results from the US reporting sustained CD4+ cell response in patients receiving zalcitabine in addition to zidovudine. This model was then adapted and applied to 5 European countries to assess the comparative cost effectiveness of adding zaldtabine to antiviral treatment for AIDS patients. The countries included in the modelling effort were Switzerland, France, Italy, Germany and the UK. The model used a Markov state-transition process to estimate the rate of acute opportunistic disease episodes, li fetime medical treatment costs, and survival for pop. ulations of AIDS patients with baseline CD4+ counts of less than 300/]l1. Physic ian panels in each country developed standard treatment algorithms and adjusted the epidemiological data to renect the AIDS profile of each country. Economic consultants provided cost data. Results from this exploratory data analysis show that if CD4+ counts correlate with the incidence of opportunistic disease episodes as expected, the combined use of zalcitabine and zidovudinc for a 1-year period should be cost effective.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Zidovudine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acquire Immune Deficiency Syndrome</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Zalcitabine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acquire Immune Deficiency Syndrome Patient</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medical Care System</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hatzialldreu, Evi J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Anderssoll, Fredrik</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shakespeare, Annabelle</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oleksy, Jnga</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tosteson, Anna N.A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">PharmacoEconomics</subfield><subfield code="d">Berlin [u.a.] : Springer, 1992</subfield><subfield code="g">6(1994), 6 vom: Dez., Seite 553-562</subfield><subfield code="w">(DE-627)327645717</subfield><subfield code="w">(DE-600)2043876-X</subfield><subfield code="x">1179-2027</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:6</subfield><subfield code="g">year:1994</subfield><subfield code="g">number:6</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:553-562</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00019053-199406060-00008</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">6</subfield><subfield code="j">1994</subfield><subfield code="e">6</subfield><subfield code="c">12</subfield><subfield code="h">553-562</subfield></datafield></record></collection>
|
| score |
7.4017296 |